Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT ID: NCT00387699

Last Updated: 2015-04-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 79 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-10-31
• Study Completion Date: 2014-04-30

Brief Summary

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and help kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving bevacizumab together with cisplatin, etoposide, and radiation therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving bevacizumab together with cisplatin, etoposide, and radiation therapy works in treating patients with limited-stage small cell lung cancer.

Detailed Description

OBJECTIVES:

Primary

• Determine the 1-year progression-free survival of patients with limited-stage small cell lung cancer treated with bevacizumab, cisplatin, etoposide, and radiotherapy.

Secondary

• Determine the toxicity of this regimen in these patients.
• Determine the response rate in patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive cisplatin IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1 and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. During course 1, patients also undergo thoracic radiotherapy twice daily on days 1-5, 8-12, and 15-19.

Patients achieving a complete or partial response or stable disease after the first 4 courses of chemotherapy continue to receive bevacizumab IV over 30-90 minutes on day 1. Treatment with bevacizumab repeats every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.

Within 4-6 weeks after blood counts recover from the first 4 courses of chemotherapy, patients achieving a complete or partial response also undergo prophylactic cranial irradiation (PCI) in 10 fractions over 3 weeks.*

NOTE: *Bevacizumab should not be given for 3 weeks prior to or during PCI, but resumed 1 week after completion of PCI.

After completion of study treatment, patients are followed periodically for 10 years.

PROJECTED ACCRUAL: A total of 79 patients will be accrued for this study.

Conditions

Lung Cancer

Study Design

• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

bevacizumab

Intervention Type: BIOLOGICAL

cisplatin

Intervention Type: DRUG

etoposide

Intervention Type: DRUG

radiation therapy

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed small cell lung cancer (SCLC)

• Limited-stage disease, defined as SCLC confined to ≥ 1 of the following:

• One hemithorax
• Ipsilateral supraclavicular fossa
• Measurable disease
• No malignant pleural effusion, contralateral hilar disease, or contralateral supraclavicular disease

• Minimal pleural effusion visible on CT scan of the chest, but not evident on chest x-ray, allowed
• No completely surgically resected disease
• No CNS disease, including primary brain tumor or brain metastasis

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2
• Absolute granulocyte count ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Bilirubin ≤ 1.5 mg/dL
• Creatinine ≤ 1.5 mg/dL
• Urine protein:creatinine ratio ≤ 0.5 OR 24-hour urine protein < 1,000 mg
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for ≥ 6 months after completion of study treatment
• INR ≤ 1.5 (unless on full-dose anticoagulants)
• No active serious infection
• No serious or nonhealing wound
• No ulcer or bone fracture
• No evidence of bleeding diatheses or coagulopathy
• No hemoptysis
• No known hypersensitivity to Chinese hamster ovary cell products and/or other recombinant human antibodies
• No clinically significant cardiovascular disease, including any of the following:

• Uncontrolled hypertension
• New York Heart Association class II-IV congestive heart failure
• Serious cardiac arrhythmia requiring medication
• Unstable angina pectoris
• Symptomatic peripheral vascular disease
• Cerebrovascular accident within the past 6 months
• Symptomatic heart disease within the past 6 months
• Myocardial infarction within the past 6 months
• Unstable angina within the past 6 months
• No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 4 weeks
• No significant traumatic injury within the past 4 weeks

PRIOR CONCURRENT THERAPY:

• At least 4 weeks since prior major surgery or open biopsy
• At least 1 week since prior core biopsy
• No prior chemotherapy or radiotherapy for small cell lung cancer
• No concurrent major surgery
• No concurrent palliative local radiotherapy
• No concurrent intensity-modulated radiotherapy
• Concurrent full-dose anticoagulants (e.g., warfarin) allowed provided all of the following criteria are met:

• INR ≤ 3
• In-range INR (2-3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin
• No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

Eastern Cooperative Oncology Group

NETWORK

Sponsor Role: lead

Responsible Party

ECOG Group Chair's Office

Principal Investigators

Afshin Dowlati, MD

Role: STUDY_CHAIR

Case Comprehensive Cancer Center

James A. Bonner, MD

Role:

University of Alabama at Birmingham

Other Identifiers

ECOG-E1506

Identifier Type: -

Identifier Source: secondary_id

CDR0000508653

Identifier Type: -

Identifier Source: org_study_id